Biomarkers in schizophrenia: a brief conceptual consideration. - Wikidata - awgldk - TriplyDB

Biomarkers in schizophrenia: a brief conceptual consideration.

Biomarkers in schizophrenia: a brief conceptual consideration.

http://www.wikidata.org/entity/Q37176633

about

A Metaanalysis of Perceptual Organization in Schizophrenia, Schizotypy, and Other High-Risk Groups Based on Variants of the Embedded Figures Task From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia Multidimensional mapping method using an arrayed sensing system for cross-reactivity screening Unravelling socio-motor biomarkers in schizophrenia.Theranostic Biomarkers for Schizophrenia The use of clinical and biological characteristics to predict outcome following First Episode Psychosis.Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry.Metabolomic Profiling of Post-Mortem Brain Reveals Changes in Amino Acid and Glucose Metabolism in Mental Illness Compared with Controls Targeting of NMDA receptors in new treatments for schizophrenia.Schizophrenia biomarkers: translating the descriptive into the diagnostic.Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis.The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring.Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels.Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder.Personalized medicine for schizophrenia.Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation.Assessment of Cognition and Personality as Potential Endophenotypes in the Western Australian Family Study of Schizophrenia.Carbonyl Stress and Microinflammation-Related Molecules as Potential Biomarkers in Schizophrenia.C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls

P2860

Q26768572-9899056B-816C-479B-9EFE-E2C574016DB9 Q28067617-B2E141E8-0C0D-4E6F-A27F-3DDE8B505F98 Q28068871-82B64BF1-6734-46AF-90BA-A33A8818F5B8 Q28542887-C1227938-DEC6-48B1-ABA8-D8E22C10B9C1 Q28544674-846C52AA-DBEB-4BAA-9170-6479576E5C87 Q30852780-3AC9548F-4A11-4CA2-B46E-514318165E25 Q33624412-E3EB35C1-9858-4056-9AF5-964D1C473B80 Q35457414-72473DB6-02A0-4A8B-B33C-D65EEE915988 Q36152491-58DD250E-4D57-4EF5-B728-A4A828F80F56 Q36743314-4D90B89B-9A14-4689-B767-AC65FE4309B6 Q38223276-E831F49A-06BB-40F7-803A-3D9B89426053 Q38324251-1BE41655-52A1-48E4-837C-FC87698DDDD6 Q38662607-FC2E2BBB-776D-49FC-A53C-09D63AD7A9FF Q39029444-BFF8DDAE-4410-4D95-B1D9-3D1F127C5CB7 Q41628681-BB32E8E9-8BBB-4EB2-A30A-E032805AF856 Q41707195-14C53270-5E4D-4BDA-979E-688D58EBD1B1 Q42347524-A30E9EF6-240E-4487-9ED6-DF6879C149FC Q47099376-54CD788C-BD13-4AE2-9534-2A30DA375628 Q47595201-A6774B34-6429-4295-8E9D-31E6CA61FD4A Q54961738-B9C674FA-C2C0-4A56-A5C8-E1B4E8B74FFE Q58575852-019FA5A8-8911-4F85-BB73-0293EA2BC5D9

P2860

Biomarkers in schizophrenia: a brief conceptual consideration.

http://www.wikidata.org/entity/Q37176633

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biomarkers in schizophrenia: a brief conceptual consideration.

@en

Biomarkers in schizophrenia: a brief conceptual consideration.

@nl

type

label

Biomarkers in schizophrenia: a brief conceptual consideration.

@en

Biomarkers in schizophrenia: a brief conceptual consideration.

@nl

prefLabel

Biomarkers in schizophrenia: a brief conceptual consideration.

@en

Biomarkers in schizophrenia: a brief conceptual consideration.

@nl

P1433

Q37176633-56C272C3-E788-493F-9F8D-83F4BB0E5758

P1476

Q37176633-663DD55C-EBF4-4423-BF4F-DDA07D8BA7AF

P2093

Q37176633-0D9EF27F-81E7-4678-9EC4-3476B9483AC3

Q37176633-AD2C3E19-782C-46C2-BD8B-7202449A6030

P2860

Q37176633-093945D8-2ABB-469C-97C0-87CA0D333255

Q37176633-10225830-1A26-4E5C-8C39-1592F5D6CA39

Q37176633-1659ED60-42CB-4188-A91F-2D0A3B099B45

Q37176633-20C3BC1A-B3E7-4009-9C5A-ADB727D5C1A4

Q37176633-34B33068-09DB-4F34-9A52-46D5FF9DE350

Q37176633-36103C68-F5C4-4CA1-885A-DBE33DD1D2AB

Q37176633-3732CAFE-7C08-4D17-AF14-E41CE77DE47D

Q37176633-667E1FCA-96AE-4A0B-96C4-2BA50206D054

Q37176633-686EB07E-A068-4E11-BB5B-09FC6B2008D2

Q37176633-741DFC48-768A-4CED-9100-6023C7F503BB

P304

Q37176633-6223F622-3EFF-43BD-968C-94E1E45A50EC

P31

Q37176633-FA2A9278-1892-4222-A358-297E4A566605

P356

Q37176633-CA028167-6BFF-4E8E-B493-715BDA6C9312

P433

Q37176633-2114F5E5-17F9-4FBA-83BD-D7FCBF9C7932

P478

Q37176633-2B0E6F0A-1747-4DDD-8F41-FDC1088E1EFD

P50

Q37176633-AF5E59D7-993C-4A5B-BCAC-73BF881AC81B

Q37176633-D13279BD-A77B-4D9D-9323-E2503F56151B

P577

Q37176633-72F096C6-62BA-492D-8355-B5E505D99E04

P5875

Q37176633-F913E20B-8FB5-4946-B036-6800E7CEA51D

P698

Q37176633-9E5BDFFD-BF30-43EF-9C1E-13FC16692A1F

P921

Q37176633-2E5442A8-ED28-4D60-B603-FD64CE35DCBB

Q37176633-606082C8-6275-4D9B-9432-8E50ACFECBED

P932

Q37176633-0818FF3D-B50D-4B4F-BAC6-588B3CC91DB6

P356

P1433

Disease Markers

P1476

Biomarkers in schizophrenia: a brief conceptual consideration.

@en

P2093

Anil Pillai

http://www.w3.org/2001/XMLSchema#string

Peter F Buckley

http://www.w3.org/2001/XMLSchema#string

P2860

Will the Kraepelinian dichotomy survive DSM-V?

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

Glucocorticoid receptor 1B and 1C mRNA transcript alterations in schizophrenia and bipolar disorder, and their possible regulation by GR gene variants.

Gene expression analysis implicates a death receptor pathway in schizophrenia pathology

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort

Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/510402

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Cynthia Shannon Weickert

Thomas W Weickert

P577

2013-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258117663

http://www.w3.org/2001/XMLSchema#string

P698

24167344

http://www.w3.org/2001/XMLSchema#string

P921

P932

3774970

http://www.w3.org/2001/XMLSchema#string